Catheter Precision (VTAK) received notification from the United States Patent and Trademark Office of the allowance for issuance of two new patents. One patent is entitled “Methods of Ventricular Arrhythmia Localization Using a 3D Model”. This patent is another milestone of adding to the VIVO technology intellectual property portfolio, and will be assigned to Kardionav, the joint venture between Catheter Precision and physicians to bring in new applications to cardiac ventricular therapies. The second patent is entitled, “Neurostimulation Devices and Methods”, which is oriented toward improvement of cardiac ventricular function, especially in patients with heart failure. This patent will be assigned to Cardionomix, a majority owned subsidiary of Catheter Precision. Cardionomix holds a number of patents, with the intent to pursue heart failure therapy, primarily through stimulation of certain nerve endings found in the pulmonary arteries.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on VTAK:
- Catheter Precision announces tender win, first purchase order in Croatia
- Catheter Precision announces introduction of LockeT product line into Italy
- Catheter announces first procedures in France as LockeT expansion continues
- Catheter receives notification of new patent issuance for VIVO product line
- Catheter Precision begins enrollment for LockeT Compare Study